
CONMED Corporation: updates and filings
Price
$47.18
November 20, 2026Market cap $1.5B
What Ploutos Investor adds for CONMED
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Oct 28, 2026next Jan 29, 2027
A rough estimate from when it has reported before, which has varied. The company announces the date itself.
October 2026
July 2026
June 2026
April 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 28, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 28, 2026Results of operationsForm8-K
- Jul 29, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 29, 2026Results of operationsForm8-K
- Jun 17, 2026Officer or director change, Regulation FD disclosureForm8-K
- Jun 16, 2026Employee stock plan reportfor the period to Dec 31, 2025Form11-K
- Jun 4, 2026Material agreement enteredForm8-K
- Jun 1, 2026Material agreement entered, new material financial obligationForm8-K
- May 28, 2026Conflict minerals reportFormSD
- May 20, 2026Officer or director change, amended articles or bylaws, shareholder voteForm8-K
- Apr 30, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Apr 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 29, 2026Results of operationsForm8-K
- Apr 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 7, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 7, 2026Additional annual meeting materialFormDEFA14A
- Apr 7, 2026Annual meeting proxy statementFormDEF 14A
- Mar 26, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 13, 2026Officer or director changeForm8-K
- Feb 17, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Jan 28, 2026Results of operationsForm8-K
- Jan 12, 2026Regulation FD disclosureForm8-K
- Jan 8, 2026Officer or director changeForm8-K
- Dec 5, 2025Regulation FD disclosureForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 28, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 28, 2026 | 8-K | Results of operations | Document |
| Jul 29, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 29, 2026 | 8-K | Results of operations | Document |
| Jun 17, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Jun 16, 2026 | 11-K | Employee stock plan reportfor the period to Dec 31, 2025 | Document |
| Jun 4, 2026 | 8-K | Material agreement entered | Document |
| Jun 1, 2026 | 8-K | Material agreement entered, new material financial obligation | Document |
| May 28, 2026 | SD | Conflict minerals report | Document |
| May 20, 2026 | 8-K | Officer or director change, amended articles or bylaws, shareholder vote | Document |
| Apr 30, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Apr 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 29, 2026 | 8-K | Results of operations | Document |
| Apr 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 7, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 7, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 7, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 26, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 13, 2026 | 8-K | Officer or director change | Document |
| Feb 17, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Jan 28, 2026 | 8-K | Results of operations | Document |
| Jan 12, 2026 | 8-K | Regulation FD disclosure | Document |
| Jan 8, 2026 | 8-K | Officer or director change | Document |
| Dec 5, 2025 | 8-K | Regulation FD disclosure | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Feb 9, 1995.
The full analysis
What do CONMED's filings show?
The filings are where every one of CONMED's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.